stockrowBristol Myers Squibb Company (BMY) vs Organon & Co. (OGN)
- Bristol Myers Squibb Company BMY 62.14 −1.57%
- Organon & Co. OGN 13.87 +0.58%
Bristol Myers Squibb Company and Organon & Co. are both Drug Manufacturers General companies. Bristol Myers Squibb Company is the larger, with a market value of $129.0B against $3.6B — 35.6× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.7× against 17.3×. Bristol Myers Squibb Company grew revenue faster over the last twelve months: 4.16% against −3.21%. Bristol Myers Squibb Company has the higher net margin (18.5% vs 3.49%) and the higher return on invested capital (13.2% vs 6.26%). Both pay a dividend; Bristol Myers Squibb Company yields more (4.06% vs 0.58%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 16 and Organon & Co. on 7.
Valuation
Profitability
| Metric | BMY | OGN | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.24% | 53.12% | 73.01% |
| Operating margin | 22.65% | 13.63% | 18.34% |
| Net margin | 18.47% | 3.49% | 7.31% |
| Free cash flow margin | 18.56% | 9.38% | 18.56% |
| Return on equity | 44.01% | 20.30% | 5.80% |
| Return on assets | 9.96% | 1.58% | 2.28% |
| Return on invested capital | 13.19% | 6.26% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack